Concept to Dosing-Challenges in New Orphan Drugs
Summary: Orphan drugs make up some of the most consequential new medicines approved in the past five years. That trend is only going to accelerate, with a slate of new innovative biopharmas entering the clinic with therapies that promise to make a difference for patients who have no good options today. There’s an urgency to develop these drugs and get to market as fast as possible while maintaining a first-class development program that can withstand the rigors of regulatory scrutiny.
In this Endpoints Webinar, we’ve invited a group of experienced cancer drug developers to discuss key strategies in managing an orphan drug program.